Mutual enhancement between heparanase and vascular endothelial growth factor: A novel mechanism for melanoma progression

Cancer Letters

Volumn 308, Issue 1, 2011, Pages 100-111

  Luan, Qi ^a   Sun, Jing ^a   Li, Chunying ^a   Zhang, Guoyou ^b   Lv, Yajie ^c   Wang, Gang ^a   Li, Chengxin ^a   Ma, Cuiling ^a   Gao, Tianwen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Heparanase; MEK ERK pathway; Melanoma; Vascular endothelial growth factor (VEGF)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; COMPLEMENTARY DNA; HEPARANASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DNA TRANSFECTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; VALIDATION PROCESS;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CYTOPLASM; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCURONIDASE; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MELANOMA; RNA, MESSENGER; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79958093934     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.019     Document Type: Article

References (47)

1. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 2010, 130:28-37.
2. Miao H.Q., Liu H., Navarro E., Kussie P., Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 2006, 13:2101-2111.
3. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5:793-802.
4. Vreys V., David G. Mammalian heparanase: what is the message?. J. Cell. Mol. Med. 2007, 11:427-452.
5. Goldshmidt O., Zcharia E., Cohen M., Aingorn H., Cohen I., Nadav L., Katz B.Z., Geiger B., Vlodavsky I. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 2003, 17:1015-1025.
6. Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J. Biol. Chem. 2004, 279:23536-23541.
7. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006, 66:1455-1463.
8. Zetser A., Bashenko Y., Miao H.Q., Vlodavsky I., Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res. 2003, 63:7733-7741.
9. Sotnikov I., Hershkoviz R., Grabovsky V., Ilan N., Cahalon L., Vlodavsky I., Alon R., Lider O. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J. Immunol. 2004, 172:5185-5193.
10. Zhang Y., Li L., Wang Y., Zhang J., Wei G., Sun Y., Shen F. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2007, 358:124-129.
11. Roy M., Reiland J., Murry B.P., Chouljenko V., Kousoulas K.G., Marchetti D. Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia 2005, 7:253-262.
12. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62:179-213.
13. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12:5268-5272.
14. Cornelissen B., Oltenfreiter R., Kersemans V., Staelens L., Frankenne F., Foidart J.M., Slegers G. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl. Med. Biol. 2005, 32:431-436.
15. Graeven U., Fiedler W., Karpinski S., Ergun S., Kilic N., Rodeck U., Schmiegel W., Hossfeld D.K. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J. Cancer. Res. Clin. Oncol. 1999, 125:621-629.
16. Kanda S., Kanetake H., Miyata Y. Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059. Biochem. Biophys. Res. Commun. 2006, 345:1481-1486.
17. Fitzpatrick T.E., Lash G.E., Yanaihara A., Charnock-Jones D.S., Macdonald-Goodfellow S.K., Graham C.H. Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor. Exp. Cell Res. 2003, 283:247-255.
18. Levy-Adam F., Miao H.Q., Heinrikson R.L., Vlodavsky I., Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem. Biophys. Res. Commun. 2003, 308:885-891.
19. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 2005, 10:2986-3001.
20. Garcea G., Neal C.P., Pattenden C.J., Steward W.P., Berry D.P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 2005, 41:2213-2236.
21. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., Peretz T., Vlodavsky I., Abramovitch R. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int. J. Cancer 2006, 118:1609-1617.
22. Bar-Sela G., Kaplan-Cohen V., Ilan N., Vlodavsky I., Ben-Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 2006, 49:188-193.
23. Murry B.P., Greiter-Wilke A., Paulsen D.P., Hiatt K.M., Beltrami C.A., Marchetti D. Selective heparanase localization in malignant melanoma. Int. J. Oncol. 2005, 26:345-352.
24. Davidson B., Shafat I., Risberg B., Ilan N., Trope C.G., Vlodavsky I., Reich R. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol. Oncol. 2007, 104:311-319.
25. Dutta U., Poornachandra K.S. Heparanase and gallbladder cancer: new insights into understanding tumor growth and invasion. J. Gastroenterol. Hepatol. 2008, 23:343-344.
26. Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E., Levy-Adam F., Bashenko Y., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 2004, 279:44084-44092.
27. Zhou Y., Song B., Qin W.J., Zhang G., Zhang R., Luan Q., Pan T.J., Yang A.G., Wang H. Heparanase promotes bone destruction and invasiveness in prostate cancer. Cancer Lett. 2008, 268:252-259.
28. Zheng L., Jiang G., Mei H., Pu J., Dong J., Hou X., Tong Q. Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer 2010, 10:33.
29. Rivera R.S., Nagatsuka H., Siar C.H., Gunduz M., Tsujigiwa H., Han P.P., Katase N., Tamamura R., Ng K.H., Naomoto Y., Nakajima M., Nagai N. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol. Rep. 2008, 19:657-661.
30. Mikami S., Ohashi K., Katsube K., Nemoto T., Nakajima M., Okada Y. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol. Int. 2004, 54:556-563.
31. Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I., Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 2008, 123:2566-2573.
32. Nobuhisa T., Naomoto Y., Okawa T., Takaoka M., Gunduz M., Motoki T., Nagatsuka H., Tsujigiwa H., Shirakawa Y., Yamatsuji T., Haisa M., Matsuoka J., Kurebayashi J., Nakajima M., Taniguchi S., Sagara J., Dong J., Tanaka N. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci. 2007, 98:535-540.
33. Dhomen N., Marais R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 2007, 17:31-39.
34. Russo A.E., Torrisi E., Bevelacqua Y., Perrotta R., Libra M., McCubrey J.A., Spandidos D.A., Stivala F., Malaponte G. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int. J. Oncol. 2009, 34:1481-1489.
35. de Mestre A.M., Rao S., Hornby J.R., Soe-Htwe T., Khachigian L.M., Hulett M.D. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J. Biol. Chem. 2005, 280:35136-35147.
36. Ogishima T., Shiina H., Breault J.E., Terashima M., Honda S., Enokida H., Urakami S., Tokizane T., Kawakami T., Ribeiro-Filho L.A., Fujime M., Kane C.J., Carroll P.R., Igawa M., Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 2005, 24:6765-6772.
37. Ogishima T., Shiina H., Breault J.E., Tabatabai L., Bassett W.W., Enokida H., Li L.C., Kawakami T., Urakami S., Ribeiro-Filho L.A., Terashima M., Fujime M., Igawa M., Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 2005, 11:1028-1036.
38. de Mestre A.M., Khachigian L.M., Santiago F.S., Staykova M.A., Hulett M.D. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J. Biol. Chem. 2003, 278:50377-50385.
39. Lu W.C., Liu Y.N., Kang B.B., Chen J.H. Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 2003, 22:919-923.
40. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., Xu X. Functional erythropoietin autocrine loop in melanoma. Am. J. Pathol. 2005, 166:823-830.
41. Luan Q., Sun J., Li C., Lv Y., Li C., Wang G., Gao T. A hypothetical signaling loop with tumor progression triggered by heparanase overexpression and growth factors. Biosci. Hypotheses 2008, 1:118-120.
42. Rajkovic E., Rek A., Krieger E., Kungl A.J. Molecular insight into human heparanase and tumour progression. Gene Ther. Mol. Biol. 2004, 8:523-528.
43. Smalley K.S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int. J. Cancer 2003, 104:527-532.
44. Purushothaman A., Chen L., Yang Y., Sanderson R.D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283:32628-32636.
45. Estrada Y., Dong J., Ossowski L. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 2009, 22:66-76.
46. Meier F., Busch S., Lasithiotakis K., Kulms D., Garbe C., Maczey E., Herlyn M., Schittek B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 2007, 156:1204-1213.
47. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 2006, 5:1136-1144.